1638750-95-4 ((ADU-S100 disodium salt)

FMW9ZVF53N;MIW815;ADU S100 [WHO-DD];Unii-fmw9zvf53N;MIW815 disodium salt;ML RR-S2 CDA disodium salt;ADU-S100 disodium salt;(2',3')-Rp,Rpc-diAMPS disodium;ADENOSINE, (P(R))-5'-O-((R)-HYDROXYMERCAPTOPHOSPHINYL)-P-THIOADENYLYL-(2'->5')-, CYCLIC NUCLEOTIDE, SODIUM SALT (1:2);ML RR-S2 CDA Sodium Salt;ADU-S100;disodium;(1R,6R,8R,9R,10S,15R,17R,18R)-8,17-bis(6-aminopurin-9-yl)-3,12-dioxido-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3;1638750-95-4;[P(R)]-5'-O-[(R)-Hydroxymercaptophosphinyl]-P-thioadenylyl-(2'?5')-adenosine cyclic nucleotide disodium;BM176133;NVP-MIW815;1638750-95-4 (sodium);ML RR-S2 CDA disodium;MW-815;E5-diphosphatricyclo[13.2.1.06,10]octadecane-9,18-diol;ADU-S100?;E5,12;disodium;(1R,6R,8R,9R,10S,15R,17R,18R)-8,17-bis(6-aminopurin-9-yl)-3,12-dioxido-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecane-9,18-diol;Sting-activating cyclic dinucleotide agonist MIW815;Cdn agonist adu-S100;

GDWOOOCBNOMMTL-QYUKNOIISA-L

1S/C20H24N10O10P2S2.2Na/c21-15-9-17(25-3-23-15)29(5-27-9)19-12(32)13-8(38-19)2-36-42(34,44)40-14-11(31)7(1-35-41(33,43)39-13)37-20(14)30-6-28-10-16(22)24-4-26-18(10)30;;/h3-8,11-14,19-20,31-32H,1-2H2,(H,33,43)(H,34,44)(H2,21,23,25)(H2,22,24,26);;/q;2*+1/p-2/t7-,8-,11-,12-,13-,14-,19-,20-,41?,42?;;/m1../s1

S=P1([O-])OC[C@@H]2[C@H]([C@H]([C@H](N3C=NC4C(N)=NC=NC3=4)O2)O)OP([O-])(OC[C@@H]2[C@H]([C@H]([C@H](N3C=NC4C(N)=NC=NC3=4)O2)O1)O)=S.[Na+].[Na+]